Previous studies have shown that patients with hepatocellular carcinoma treated with sorafenib have decreased serum carnitine levels and sarcopenia, effects that may be attributed to the inhibition of OCTN2 by sorafenib [34] and our results confirmed that decreased carnitine content due to the knockdown of OCTN2 results in muscle wasting. This evidence concerns the gene SLC22A5 and hepatocellular carcinoma.